TY - JOUR
T1 - Liver cirrhosis
AU - Ginès, Pere
AU - Krag, Aleksander
AU - Abraldes, Juan G.
AU - Solà, Elsa
AU - Fabrellas, Núria
AU - Kamath, Patrick S.
N1 - Funding Information:
We dedicate this work to the memories of Prof Juan Rodés and Robert W Schier. PG is supported by the grants LiverHope 731875 and LiverScreen 847989 (European Commission Horizon 2020), FIS PI20/00579 (integrated in the Plan Nacional I+D+I and co-funded by ISCIII-Subdirección General de Evaluación and European Regional Development Fund), by Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, and by the Agency for Management of University and Research Grant grant number AGAUR 2017_SGR_01281. NF is supported by the grant FIS 18/01330 (integrated in the Plan Nacional I+D+I and co-funded by ISCIII-Subdirección General de Evaluación and European Regional Development Fund). PSK is partly supported by the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism grant U01AA26974. We acknowledge the support of Nicki van Berckel and Roser Poblet in the preparation of this Seminar and the expert technical assistance of Stine Johansen in drawing figure 2 .
Funding Information:
We dedicate this work to the memories of Prof Juan Rod?s and Robert W Schier. PG is supported by the grants LiverHope 731875 and LiverScreen 847989 (European Commission Horizon 2020), FIS PI20/00579 (integrated in the Plan Nacional I+D+I and co-funded by ISCIII-Subdirecci?n General de Evaluaci?n and European Regional Development Fund), by Centro de Investigaci?n Biom?dica en Red de Enfermedades Hep?ticas y Digestivas, and by the Agency for Management of University and Research Grant grant number AGAUR 2017_SGR_01281. NF is supported by the grant FIS 18/01330 (integrated in the Plan Nacional I+D+I and co-funded by ISCIII-Subdirecci?n General de Evaluaci?n and European Regional Development Fund). PSK is partly supported by the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism grant U01AA26974. We acknowledge the support of Nicki van Berckel and Roser Poblet in the preparation of this Seminar and the expert technical assistance of Stine Johansen in drawing figure 2.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/10/9
Y1 - 2021/10/9
N2 - Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as obesity, non-alcoholic fatty liver disease, high alcohol consumption, hepatitis B or C infection, autoimmune diseases, cholestatic diseases, and iron or copper overload. Cirrhosis develops after a long period of inflammation that results in replacement of the healthy liver parenchyma with fibrotic tissue and regenerative nodules, leading to portal hypertension. The disease evolves from an asymptomatic phase (compensated cirrhosis) to a symptomatic phase (decompensated cirrhosis), the complications of which often result in hospitalisation, impaired quality of life, and high mortality. Progressive portal hypertension, systemic inflammation, and liver failure drive disease outcomes. The management of liver cirrhosis is centred on the treatment of the causes and complications, and liver transplantation can be required in some cases. In this Seminar, we discuss the disease burden, pathophysiology, and recommendations for the diagnosis and management of cirrhosis and its complications. Future challenges include better screening for early fibrosis or cirrhosis, early identification and reversal of causative factors, and prevention of complications.
AB - Cirrhosis is widely prevalent worldwide and can be a consequence of different causes, such as obesity, non-alcoholic fatty liver disease, high alcohol consumption, hepatitis B or C infection, autoimmune diseases, cholestatic diseases, and iron or copper overload. Cirrhosis develops after a long period of inflammation that results in replacement of the healthy liver parenchyma with fibrotic tissue and regenerative nodules, leading to portal hypertension. The disease evolves from an asymptomatic phase (compensated cirrhosis) to a symptomatic phase (decompensated cirrhosis), the complications of which often result in hospitalisation, impaired quality of life, and high mortality. Progressive portal hypertension, systemic inflammation, and liver failure drive disease outcomes. The management of liver cirrhosis is centred on the treatment of the causes and complications, and liver transplantation can be required in some cases. In this Seminar, we discuss the disease burden, pathophysiology, and recommendations for the diagnosis and management of cirrhosis and its complications. Future challenges include better screening for early fibrosis or cirrhosis, early identification and reversal of causative factors, and prevention of complications.
UR - http://www.scopus.com/inward/record.url?scp=85116715095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116715095&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)01374-X
DO - 10.1016/S0140-6736(21)01374-X
M3 - Review article
C2 - 34543610
AN - SCOPUS:85116715095
SN - 0140-6736
VL - 398
SP - 1359
EP - 1376
JO - The Lancet
JF - The Lancet
IS - 10308
ER -